Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E16.10 EPS (ttm)17.69 Insider Own0.10% Shs Outstand219.88M Perf Week-3.47%
Market Cap62.61B Forward P/E13.55 EPS next Y21.02 Insider Trans-13.35% Shs Float216.61M Perf Month-0.92%
Income3.89B PEG1.72 EPS next Q4.98 Inst Own88.40% Short Float0.96% Perf Quarter-3.28%
Sales11.42B P/S5.48 EPS this Y24.00% Inst Trans0.01% Short Ratio1.19 Perf Half Y9.39%
Book/sh55.36 P/B5.14 EPS next Y4.07% ROA18.50% Target Price341.12 Perf Year1.49%
Cash/sh19.63 P/C14.51 EPS next 5Y9.36% ROE36.00% 52W Range223.02 - 333.65 Perf YTD0.41%
Dividend- P/FCF19.23 EPS past 5Y31.30% ROI23.50% 52W High-14.66% Beta0.72
Dividend %- Quick Ratio2.80 Sales past 5Y17.90% Gross Margin87.50% 52W Low27.68% ATR7.11
Employees7350 Current Ratio3.20 Sales Q/Q6.40% Oper. Margin47.60% RSI (14)39.66 Volatility2.29% 2.13%
OptionableYes Debt/Eq0.54 EPS Q/Q13.40% Profit Margin34.00% Rel Volume0.97 Prev Close287.77
ShortableYes LT Debt/Eq0.54 EarningsJan 26 BMO Payout0.00% Avg Volume1.75M Price284.75
Recom2.10 SMA20-1.38% SMA50-3.78% SMA200-0.27% Volume1,692,420 Change-1.05%
Dec-29-16Reiterated Raymond James Strong Buy $375 → $386
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jan-13-17 06:39PM  Is Biogen's Stock Ready to Heat Up After a Forgettable 2016? at Motley Fool
02:20PM  Biogen's latest drug may be costly, but new data suggests it saves lives at
01:32PM  Top Research Reports for Alibaba, Costco & Walgreens
10:16AM  Biogen Spinoff Bioverativ In Good Shape for Launch at Investopedia
09:55AM  Ionis Has High Hopes for Heart Drug Volanesorsen at Investopedia
08:31AM  Bioverativ Makes Splash in Trading Debut, Gaining 18% on Day One
07:30AM  New Data Show SPINRAZA (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy Business Wire
Jan-12-17 05:10PM  Trumps HHS nominee has promised to divest from these Mass. companies at
09:35AM  Biotech Short Sellers Run for Cover
08:00AM  Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock Business Wire
Jan-11-17 06:38PM  Choppy Day As Trump Targets Pharma, Lockheed; Netflix, Amazon Up
01:59PM  Trump's Comments Slam Drug Stocks at The Wall Street Journal
01:25PM  Trump slams drug industry at press conference, sending biotech stocks tumbling at
01:23PM  The 1 Biotech Stock I Want to Own in 2017 at Motley Fool
10:27AM  Biogen, Inc. Value Analysis (NASDAQ:BIIB) : January 11, 2017
Jan-10-17 12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes
11:54AM  3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock at Motley Fool
11:01AM  Biogen CEO Vounatsos on Drug Pipeline, Pricing
09:39AM  Top Stocks to Buy Now That the 21st Century Cures Act Has Passed at Motley Fool
07:26AM  Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : January 10, 2017
Jan-09-17 01:01PM  This Could Very Well Be the Greatest Drug Advancement in a Decade at Motley Fool
Jan-08-17 02:00PM  3 Takeover Candidates in the Drug Space
Jan-06-17 07:25PM  Biogen's New CEO: Lots of Questions, Few Answers at Motley Fool
07:21PM  Biotech icon George Scangos returns to Bay Area with big startup at
10:55AM  Biotech Investing: 3 Bold Predictions for 2017 at Motley Fool
09:07AM  What Were Incytes Revenue Streams in 3Q16?
08:32AM  Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
07:05AM  New Biogen CEO explains hefty price tag for newest drug at
Jan-05-17 04:55PM  5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to See at Motley Fool
02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at
12:43PM  Drug Price Debate May Lead to Smaller Price Hikes at Investopedia
12:30PM  Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology Marketwired
11:04AM  Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting
06:54AM  Is Biogen Playing With Fire? at Motley Fool
06:21AM  What Biotech Investors Can Expect from the J.P. Morgan Healthcare Conference 2017
Jan-04-17 05:19PM  Buy health care despite Obamacare battle?
11:55AM  Did Biogen Just Throw in the Towel to Celgene? at Motley Fool
10:57AM  Biogen, Ionis Under Fire for Pricey Drug Spinraza at Investopedia
07:21AM  Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
Jan-03-17 05:41PM  My Worst Predictions for Biotech in 2016 at Motley Fool
02:42PM  New year, new drug prices
01:30PM  Biogen boosts price of top MS drugs, analyst says at
06:35AM  17 Thoughts on Biotech Stocks to Kick Off 2017
Jan-02-17 11:54AM  Biotech Stocks: What to Watch in 2017 at Motley Fool
Dec-30-16 04:16PM  Gilead Sciences Valuation Compared to Its Peers
12:45PM  Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains?
09:23AM  Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It
06:59AM  Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says at MarketWatch
Dec-29-16 04:09PM  Investors Siphon Biogen, Ionis Gains After Spinal Disease Drug's OK
04:07PM  Texas Instruments A Buy; Biogen, 21st Century Fox PTs Hiked at Investor's Business Daily
01:23PM  Red flag over Biogen's very expensive drug
10:10AM  Analyst hikes sales estimates for Biogens spinal-disease drug at
10:03AM  Biogen: Starting the New Year Off With a Bang? at
Dec-28-16 05:39PM  Why Twilio, Northern Dynasty Minerals, and Ionis Pharmaceuticals Slumped Today at Motley Fool
05:22PM  Will Spinraza Supercharge Biogen's Top Line Next Year? at Motley Fool
01:43PM  Biogen Could Suffer Near Term as the Chart Picture Erodes
10:10AM  Biotech Short Interest Sinks
07:32AM  Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold
07:23AM  The 3 Biggest Risks for Pfizer in 2017 at Motley Fool
06:52AM  Biotech plays for the new year
Dec-27-16 11:43PM  [$$] Surprise Drug Approval Is Holiday Gift for Biogen at The Wall Street Journal
03:53PM  3 Biggest Risks for AbbVie in 2017 at Motley Fool
02:45PM  Time for biotech to boom ... or bust?
02:32PM  Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
12:07PM  Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval at TheStreet
11:34AM  [$$] Surprise Drug Approval Is Holiday Gift for Biogen at The Wall Street Journal
10:56AM  Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis
10:42AM  Why Ionis Approval Could Lift Biogen 25% at
10:18AM  [$$] Ionis and Biogen's Spinraza Drug Wins FDA Approval at The Wall Street Journal
10:10AM  Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug
10:05AM  Top Analysts Upgrades and Downgrades: Biogen, FedEx, Lions Gate, Rexnord, Ionis Pharmaceutical and More at 24/7 Wall St.
10:02AM  US STOCKS-Dow nears 20,000, Nasdaq hits record as tech stocks gain
09:13AM  Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
08:56AM  US STOCKS-Wall St set to open flat after Christmas
07:45AM  Early movers: BIIB, IONS, FRED, TSLA, SNE, DIS & more at CNBC
07:36AM  US STOCKS-Futures slightly higher after Christmas holiday
07:30AM  Exclusive Q&A: Ionis CEO Sees Watershed 2017 On 'Rapid' Drug OKs
Dec-26-16 10:55PM  Coming soon to the Nasdaq: Biogen's hemophilia spinoff at
01:30PM  5 Trade Ideas for Tuesday: Ashland, Biogen, Crown Castle, Monster and Norfolk Southern
Dec-23-16 08:16PM  The FDA's Christmas Breakthrough at Forbes
04:53PM  FDA approves Biogen drug for lead genetic cause of infant death Reuters
04:51PM  U.S. FDA Approves Biogens SPINRAZA (nusinersen), The First Treatment for Spinal Muscular Atrophy Business Wire
09:06AM  Celgene, Evotec Target Unmet Demand in Neurodegenerative Segment
Dec-22-16 06:14PM  Health Care Companies Showing Good Defensive Potential
04:36PM  Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement Business Wire
11:20AM  What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
10:15AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016 Accesswire
09:36AM  2016's Worst Clinical Failures at Motley Fool
08:25AM  RBC Likes Large Cap Biotech Leaders for 2017 at 24/7 Wall St.
08:00AM  Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017 Business Wire
Dec-21-16 08:00PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm Accesswire
04:17PM  Celgene Expects Strong Revenue Growth in 2016
04:17PM  Biogen Likely To Trim EPS View On Hemophilia Spinoff, Floundering MS Unit
04:01PM  Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference Business Wire
01:33PM  Biotech Giant Biogen To Spin-Off Bioverativ at Forbes
12:54PM  INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016 Accesswire
09:25AM  Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug
08:41AM  Biogen (BIIB) Board Okays Hemophilia Business Spin-off
08:00AM  Biogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017 Business Wire
12:35AM  [$$] Biogen Faces No Easy Opportunities at The Wall Street Journal
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PANGIA ROBERT WDirectorJan 09Option Exercise52.225,450284,59922,078Jan 10 04:15 PM
PANGIA ROBERT WDirectorJan 09Sale295.395,4501,609,87616,628Jan 10 04:15 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM